Tag Archives: NYSE:JNJ

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Ionis Pharmaceuticals (NASDAQ: IONS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ – Research Report) and Ionis Pharmaceuticals (IONS – Research Report). Johnson & Johnson (JNJ) In a report issued on February 13,

Credit Suisse Maintains a Buy Rating on Johnson & Johnson (JNJ)

In a report issued on May 17, Matt Miksic from Credit Suisse maintained a Buy rating on Johnson & Johnson (JNJ – Research Report). The company’s shares closed last Thursday at $147.19. According to TipRanks.com, Miksic is a 5-star analyst

Credit Suisse Believes Johnson & Johnson (NYSE: JNJ) Still Has Room to Grow

Credit Suisse analyst Matt Miksic maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) on August 23. The company’s shares closed last Thursday at $149.55, close to its 52-week high of $157.00. According to TipRanks.com, Miksic is

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Pacira Pharmaceuticals (NASDAQ: PCRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Johnson & Johnson (JNJ – Research Report) and Pacira Pharmaceuticals (PCRX – Research Report) with bullish sentiments. Johnson & Johnson (JNJ) In

Credit Suisse Believes Johnson & Johnson (NYSE: JNJ) Won’t Stop Here

In a report released today, Matt Miksic from Credit Suisse reiterated a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price target of $161.00. The company’s shares closed last Tuesday at $152.33, close to its 52-week

Morgan Stanley Keeps a Buy Rating on Johnson & Johnson (JNJ)

In a report released today, David Lewis from Morgan Stanley maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price target of $160.00. The company’s shares closed last Monday at $124.30. According to TipRanks.com, Lewis